SCHEMBL3183226

SCHEMBL3183226

NCCN(CCN)CCCN(CCN)CCN

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LCK P06239 2/20 0.62
NFKB1 P19838 1/20 0.33
CHRM2 P08172 1/20 0.32
CA12 O43570 2/20 0.31
CA1 P00915 2/20 0.31
CA2 P00918 2/20 0.31
CA3 P07451 2/20 0.31
CA4 P22748 2/20 0.31
CA6 P23280 2/20 0.31
CA5A P35218 2/20 0.31
CA7 P43166 2/20 0.31
CA9 Q16790 2/20 0.31
CA14 Q9ULX7 2/20 0.31
CA5B Q9Y2D0 2/20 0.31
DNM1 Q05193 1/20 0.31
LMNA P02545 1/20 0.31
TSHR P16473 1/20 0.31
BLM P54132 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2055294 0.92 LCK (0.55) LCKNFKB1CHRM2CA12CA1
SCHEMBL7166448 0.89 LCK (0.52) LCKNFKB1CHRM2CA12CA1
SCHEMBL2055293 0.89 LCK (0.52) LCKNFKB1CHRM2
SCHEMBL176516 0.89 LCK (0.52) LCKNFKB1CHRM2CA12CA1
SCHEMBL43276 0.89 LCK (0.52) LCKNFKB1CHRM2CA12CA1
SCHEMBL33394 0.88 LCK (0.48) LCKNFKB1CHRM2LMNA
SCHEMBL1062510 0.88 LCK (0.48) LCKNFKB1CHRM2LMNA
SCHEMBL17123446 0.87 LCK (0.52) LCKNFKB1CHRM2CA12CA1
SCHEMBL15591980 0.87 LCK (0.52) LCKNFKB1CHRM2CA12CA1
SCHEMBL23549865 0.86 LCK (0.50) LCKNFKB1CHRM2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116211887-A Composition for treating acid-base imbalance 特里赛达公司 2023-06-06 CN claimed
CN-111671766-A Proton-binding polymers for oral administration 特里赛达公司 2020-09-18 CN claimed
CN-111671767-A Proton-binding polymers for oral administration 特里赛达公司 2020-09-18 CN claimed
CN-105377270-B Proton-binding polymers for oral administration 特里赛达公司 2020-09-04 CN claimed
US-20190209607-A1 COMPOSITIONS FOR TREATING ACID-BASE DISORDERS TRICIDA, INC. 2019-07-11 US claimed
EP-3287133-B1 PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION TRICIDA INC (US) 2019-04-17 EP claimed
CN-109414453-A composition for treating acid-base imbalance 特里赛达公司 2019-03-01 CN claimed
EP-3812761-B1 PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION RENOSIS INC (US) 2025-12-24 EP disclosed
US-20250222021-A1 METHOD OF TREATING ACID-BASE DISORDERS RENIBUS THERAPEUTICS, INC. 2025-07-10 US disclosed
EP-4572882-A1 PROCESS FOR PRODUCING MICROPARTICLES BASF SE (DE) 2025-06-25 EP disclosed
US-20250025494-A1 COMPOSITIONS FOR AND METHOD OF TREATING ACID-BASE DISORDERS RENIBUS THERAPEUTICS, INC. 2025-01-23 US disclosed
US-20250009785-A1 HCL-BINDING COMPOSITIONS FOR AND METHODS OF TREATING ACID-BASE DISORDERS RENIBUS THERAPEUTICS, INC. 2025-01-09 US disclosed
US-11992501-B2 Compositions for and methods of treating acid-base disorders RENOSIS, INC. (US) 2024-05-28 US disclosed
EP-2044090-A2 LUMINESCENT 1-HYDROXY-2-PYRIDINONE CHELATES OF LANTHANIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-04-08 EP disclosed
WO-2008008797-A2 LUMINESCENT 1-HYDROXY-2-PYRIDINONE CHELATES OF LANTHANIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-01-17 WO disclosed
EP-0840727-B1 3-HYDROXY-2(1H)-PYRIDINONE CHELATING AGENTS UNIV CALIFORNIA (US) 2004-05-06 EP disclosed
US-5892029-A HIGHLY EFFECTIVE UPON BOTH INJECTION AND ORAL ADMINISTRATION. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-04-06 US disclosed
EP-0840727-A1 3-HYDROXY-2(1H)-PYRIDINONE CHELATING AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-05-13 EP disclosed
US-5624901-A CARBAMOYL SUBSTITUTED COMPOUNDS FOR CHELATE COMPOUNDS FOR MAGNETIC RESONANCE IMAGING THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-04-29 US disclosed
WO-1997000245-A1 3-HYDROXY-2(1H)-PYRIDINONE CHELATING AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11992501-B2 Compositions for and methods of treating acid-base disorders SLC10A2, SLC10A1, SLC26A3 LCK 4788/4885NFKB1 3854/4885CHRM2 2755/4885
US-20250222021-A1 METHOD OF TREATING ACID-BASE DISORDERS SLC10A2, SLC10A1, SI LCK 4187/4885NFKB1 3884/4885CHRM2 1836/4885
US-20250009785-A1 HCL-BINDING COMPOSITIONS FOR AND METHODS OF TREATING ACID-BASE DISORDERS SLC10A2, SLC10A1, SLC7A1 LCK 4702/4885NFKB1 3059/4885CHRM2 2397/4885
US-20250025494-A1 COMPOSITIONS FOR AND METHOD OF TREATING ACID-BASE DISORDERS SLC10A2, SLC10A1, GLS LCK 3361/4885NFKB1 4147/4885CHRM2 1741/4885
US-20190209607-A1 COMPOSITIONS FOR TREATING ACID-BASE DISORDERS SLC10A2, SLC10A1, SLC26A3 LCK 4777/4885NFKB1 3257/4885CHRM2 2467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.